Sarah Boyce, President and CEO at Avidity Biosciences, Inc. (RNA), sold 600,000 shares at $40.08 ($23.2M) on 2024-06-13, disclosed to the SEC on 2024-06-14.
Scheduled sale ($23.2M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.73 | 100,000 | $3.6M | 15.4% |
| 2 | $35.73 | 100,000 | $3.6M | 15.4% |
| 3 | $40.08 | 164,233 | $6.6M | 28.4% |
| 4 | $40.08 | 164,233 | $6.6M | 28.4% |
| 5 | $40.08 | 35,767 | $1.4M | 6.2% |
| 6 | $40.08 | 35,767 |
| $1.4M |
| 6.2% |
| Total | $38.63 avg | 600,000 | $23.2M | 100% |
| Filing → |
| RNA | SELL | 2025-09-05 | $2.5M | — | Filing → |
| RNA | SELL | 2025-08-29 | $1.2M | — | Filing → |
| RNA | SELL | 2025-03-21 | $2.0M | — | Filing → |